Clinicopathological differences and correlations between right and left colon cancer.
Colorectal neoplasm
Epidermal growth factor
Histology
Metabolic syndrome
Molecular biology
Vascular endothelial growth factor
Journal
World journal of clinical cases
ISSN: 2307-8960
Titre abrégé: World J Clin Cases
Pays: United States
ID NLM: 101618806
Informations de publication
Date de publication:
26 Apr 2020
26 Apr 2020
Historique:
received:
27
12
2019
revised:
28
02
2020
accepted:
17
04
2020
entrez:
6
5
2020
pubmed:
6
5
2020
medline:
6
5
2020
Statut:
ppublish
Résumé
The differences in histopathology and molecular biology between right colon cancer (RCC) and left colon cancer (LCC) were first reported in the literature by Bufill in 1990. Since then, a large number of studies have confirmed their differences in epidemiology, clinical presentation, comorbidities and biological behaviours, which may be related to the difference in prognosis and overall survival (OS) between the two groups. To investigate statistically significant differences between Greek patients with LCC and RCC. The present observational study included 144 patients diagnosed with colon cancer of any stage who received chemotherapy in a Greek tertiary oncology hospital during a 2.5-year period. Clinical information, comorbidities, histopathologic characteristics and molecular biomarkers were collected from the patients' medical records retrospectively, while administered chemotherapy regimens, targeted agents, progression-free survival (PFS) periods with first- and second-line chemotherapy and OS were recorded retroactively and prospectively. Data analysis was performed with the SPSS statistical package. Eighty-six males and 58 females participated in the study. One hundred (69.4%) patients had a primary lesion in the left colon, and 44 (30.6%) patients had a primary lesion in the right colon. Patients with RCC were more likely to display anaemia than patients with LCC [odds ratio (OR) = 3.09], while LCC patients were more likely to develop rectal bleeding (OR = 3.37) and a feeling of incomplete evacuation (OR = 2.78) than RCC patients. Considering comorbidities, RCC patients were more likely to suffer from diabetes (OR = 3.31) and coronary artery disease ( RCC patients present more comorbidities, worse histological and molecular characteristics and a consequently higher probability of tumour recurrence, poor response to targeted therapy and shorter OS than LCC patients.
Sections du résumé
BACKGROUND
BACKGROUND
The differences in histopathology and molecular biology between right colon cancer (RCC) and left colon cancer (LCC) were first reported in the literature by Bufill in 1990. Since then, a large number of studies have confirmed their differences in epidemiology, clinical presentation, comorbidities and biological behaviours, which may be related to the difference in prognosis and overall survival (OS) between the two groups.
AIM
OBJECTIVE
To investigate statistically significant differences between Greek patients with LCC and RCC.
METHODS
METHODS
The present observational study included 144 patients diagnosed with colon cancer of any stage who received chemotherapy in a Greek tertiary oncology hospital during a 2.5-year period. Clinical information, comorbidities, histopathologic characteristics and molecular biomarkers were collected from the patients' medical records retrospectively, while administered chemotherapy regimens, targeted agents, progression-free survival (PFS) periods with first- and second-line chemotherapy and OS were recorded retroactively and prospectively. Data analysis was performed with the SPSS statistical package.
RESULTS
RESULTS
Eighty-six males and 58 females participated in the study. One hundred (69.4%) patients had a primary lesion in the left colon, and 44 (30.6%) patients had a primary lesion in the right colon. Patients with RCC were more likely to display anaemia than patients with LCC [odds ratio (OR) = 3.09], while LCC patients were more likely to develop rectal bleeding (OR = 3.37) and a feeling of incomplete evacuation (OR = 2.78) than RCC patients. Considering comorbidities, RCC patients were more likely to suffer from diabetes (OR = 3.31) and coronary artery disease (
CONCLUSION
CONCLUSIONS
RCC patients present more comorbidities, worse histological and molecular characteristics and a consequently higher probability of tumour recurrence, poor response to targeted therapy and shorter OS than LCC patients.
Identifiants
pubmed: 32368535
doi: 10.12998/wjcc.v8.i8.1424
pmc: PMC7190956
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1424-1443Informations de copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors declare no financial support, funding resources or conflicts of interest.
Références
Circulation. 2004 Sep 7;110(10):1245-50
pubmed: 15326067
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Eur J Cancer. 2015 Jul;51(11):1405-14
pubmed: 25979833
Int J Cancer. 2002 Oct 10;101(5):403-8
pubmed: 12216066
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Gut. 2012 Jun;61(6):847-54
pubmed: 22427238
World J Gastroenterol. 2015 Jun 7;21(21):6470-8
pubmed: 26074686
J Clin Oncol. 2011 May 20;29(15):2011-9
pubmed: 21502544
Eur J Cancer. 2017 Jan;70:87-98
pubmed: 27907852
Chronic Dis Transl Med. 2017 Mar 13;3(1):51-59
pubmed: 29063056
Ann Oncol. 2013 Oct;24(10):2554-9
pubmed: 23864097
Medicine (Baltimore). 2018 Mar;97(9):e0019
pubmed: 29489646
Int J Biol Markers. 2019 Mar;34(1):47-53
pubmed: 30854932
Am J Clin Oncol. 2011 Dec;34(6):573-80
pubmed: 21217399
Ann Intern Med. 1990 Nov 15;113(10):779-88
pubmed: 2240880
Ann Oncol. 2013 Sep;24(9):2342-9
pubmed: 23852309
Clin Cancer Res. 2014 Jun 1;20(11):3033-43
pubmed: 24687927
Dan Med J. 2012 Jun;59(6):A4444
pubmed: 22677242
Ann Oncol. 2017 Aug 1;28(8):1862-1868
pubmed: 28449055
Ann Oncol. 2014 Oct;25(10):1995-2001
pubmed: 25057166
J Cancer Res Clin Oncol. 2014 Sep;140(9):1607-14
pubmed: 24816724
JAMA Surg. 2015 Jan;150(1):17-22
pubmed: 25372703
Ann Surg Oncol. 2008 Sep;15(9):2388-94
pubmed: 18622647
Bull Cancer. 2008 Jan;95(1):121-32
pubmed: 18230578
Cancer Biol Ther. 2014 Jun 1;15(6):768-76
pubmed: 24642870
Crit Rev Oncol Hematol. 2015 Oct;96(1):156-66
pubmed: 26088456
Oncol Rep. 2014 Jul;32(1):50-6
pubmed: 24806883
J Surg Oncol. 2016 Dec;114(7):803-809
pubmed: 27792291
J Clin Oncol. 2008 Nov 20;26(33):5326-34
pubmed: 18854571
Clin Cancer Res. 2012 Sep 1;18(17):4753-63
pubmed: 22753589
J Clin Oncol. 2014 Jul 20;32(21):2240-7
pubmed: 24687833
J Clin Oncol. 2011 Nov 20;29(33):4401-9
pubmed: 21969498
Ann Oncol. 2017 Aug 1;28(8):1713-1729
pubmed: 28407110
Dis Colon Rectum. 2010 Jan;53(1):57-64
pubmed: 20010352
Gastroenterology Res. 2018 Aug;11(4):264-273
pubmed: 30116425
Lancet Oncol. 2013 Jan;14(1):29-37
pubmed: 23168366
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
pubmed: 24399786
J Gastroenterol Hepatol. 2008 Mar;23(3):418-23
pubmed: 17532785
Cancers (Basel). 2011 Jun 23;3(2):2767-810
pubmed: 24212832
Am J Gastroenterol. 2011 Nov;106(11):1911-21; quiz 1922
pubmed: 21912438